38720
document
Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer : results from a randomized trial . The purpose of this randomized study was to examine if goserelin concomitant to CMF-chemotherapy as adjuvant treatment for premenopausal breast cancer , protects the ovaries from premature failure . A total of 285 premenopausal breast cancer patients , in a randomized adjuvant trial ( Zoladex in premenopausal patients ( ZIPP ) ) , were assigned to a study on ovarian function . Node positive patients were assigned to CMF- ( cyclophosphamide , methotrexate and 5-fluorouracil ) chemotherapy in addition to endocrine therapy . All patients were randomly assigned to receive 2 years of goserelin , goserelin plus tamoxifen , tamoxifen alone or no endocrine treatment . We studied , if menses were affected in the treatment groups , up to 36 months after randomization . One year after completed CMF- and endocrine therapy , 36 % of the women in the goserelin group reported menses , compared to 7 % in the goserelin plus tamoxifen group , 13 % in the tamoxifen group and 10 % of the controls . Among women treated with goserelin , there was a statistically significant increase in the proportion of menstruating women , 1 year after completed treatment compared to at 24 months of treatment ( P = 0.006 ) , in contrast to all other treatment groups , who were unchanged or more often amenorrheic . In our study , there is some evidence of protective effect of goserelin on ovarian function in CMF treated women . This effect was not observed in the combined tamoxifen and goserelin treatment .
38721
Intervention_Pharmacological
Zoladex
38722
Intervention_Pharmacological
CMF- ( cyclophosphamide , methotrexate and 5-fluorouracil ) chemotherapy
38723
Intervention_Pharmacological
endocrine therapy
38724
Intervention_Pharmacological
goserelin
38725
Intervention_Pharmacological
goserelin plus tamoxifen
38726
Intervention_Pharmacological
tamoxifen alone
38727
Intervention_Control
no endocrine treatment
38728
Outcome_Mental
protects the ovaries
38729
Outcome_Pain
menses
38730
Outcome_Physical
menses
38731
Outcome_Physical
increase
38732
Outcome_Physical
proportion of menstruating women
38733
Outcome_Other
amenorrheic .
38734
Outcome_Other
protective effect of goserelin on ovarian function
38735
Participant_Condition
breast cancer
38736
Participant_Sample-size
285
38737
Participant_Condition
premenopausal breast cancer